Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008;13(1):58-66.
doi: 10.2478/s11658-007-0035-9. Epub 2007 Oct 19.

Platelet-activating factor changes in phospholipid extracts from the plasma, peripheral blood mononuclear cells and bone marrow mononuclear cells of patients with acute leukemia--a 31P MRS in vitro study

Małgorzata Kuliszkiewicz-Janus  1 , Mariusz Adam Tuz, Marek Kiełbiński, Stanisław Baczyński, Bozena Jaźwiec, Helena Sladowska
Affiliations

Platelet-activating factor changes in phospholipid extracts from the plasma, peripheral blood mononuclear cells and bone marrow mononuclear cells of patients with acute leukemia--a 31P MRS in vitro study

Małgorzata Kuliszkiewicz-Janus et al. Cell Mol Biol Lett. 2008.

Abstract

The aim of this investigation was to evaluate the changes in PAF concentrations in the plasma, PBMC and BMMC of patients with acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML). The plasma was from 23 healthy volunteers (HV) and 44 patients with AL (16 ALL, 28 AML). The PBMC were from 15 HV and 55 patients with AL (18 ALL, 37 AML), and the BMMC from 40 patients with AL (11 ALL, 29 AML). Methanol-chloroform phospholipid extraction from 60 x 10(6) cells (PBMC or BMMC) was performed according to a modified version of Folch's method. (31)P MRS data was obtained on an AMX 300 Bruker spectrometer (7.05 T). The PAF concentration in the plasma of the patients with ALL or AML was lower than that for the healthy volunteers. The PAF concentration in the plasma of the patients with ALL did not differ significantly from that of the patients with AML. In the case of both the PBMC and BMMC, the PAF concentration was significantly diminished in patients with ALL relative to the concentration for those with AML and for the healthy volunteers. No differences were observed in the PAF concentrations for the AML patients and the healthy volunteers.

PubMed Disclaimer

References

    1. Mazer B.D., Sawami H., Franklin R., Gelfand E.W. B-cell activation and regulation of immunoglobulin synthesis by platelet activating factor. Neth. J. Med. 1991;39:224–253. - PubMed
    1. Rola Pleszczynski M., Pouliot C., Turcotte S., Pignol B., Braquet P., Bouvrette L. Immune regulation by platelet-activating factor: I. induction of supressor cell activity in human monocytes and CD8+ T cells and of helper cell activity in CD4+ T cells. J. Immunol. 1988;140:3547–3552. - PubMed
    1. Demopoulos C.A., Pinckard R.N., Hanahan D.J. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators) J. Biol. Chem. 1979;254:9355–9358. - PubMed
    1. Blank M.L., Snyder F., Byers L.W., Brooks B., Muirhead E.E. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem. Biophys. Res. Commun. 1979;90:1194–1200. doi: 10.1016/0006-291X(79)91163-X. - DOI - PubMed
    1. O’Flaherty J.T., Miller C.H., Lewis J.C., Wykle R.L., Bass D.A., McCall C.E., Waite M., De Chatelet L.R. Neutrophil responses to platelet-activating factor. Inflammation. 1981;5:193–201. doi: 10.1007/BF00914443. - DOI - PubMed

Publication types

MeSH terms